2. Academic Validation
  3. Ridinilazole: a novel therapy for Clostridium difficile infection

Ridinilazole: a novel therapy for Clostridium difficile infection

  • Int J Antimicrob Agents. 2016 Aug;48(2):137-43. doi: 10.1016/j.ijantimicag.2016.04.026.
Richard J Vickers 1,  Glenn Tillotson 2,  Ellie J C Goldstein 3,  Diane M Citron 4,  Kevin W Garey 5,  Mark H Wilcox 6
Affiliations

Affiliations

  • 1 Summit Therapeutics plc, 85b Park Drive, Milton Park, Abingdon, Oxford OX14 4RY, UK. Electronic address: richard.vickers@summitplc.com.
  • 2 Cempra Pharmaceuticals, Chapel Hill, NC, USA.
  • 3 R.M. Alden Research Laboratory, Culver City, CA, USA; David Geffen School of Medicine at UCLA, Los Angeles, CA, USA.
  • 4 R.M. Alden Research Laboratory, Culver City, CA, USA.
  • 5 University of Houston College of Pharmacy, Houston, TX, USA.
  • 6 Microbiology, Leeds Teaching Hospitals and University of Leeds, Old Medical School, Leeds General Infirmary, Leeds, UK.
PMID: 27283730 DOI: 10.1016/j.ijantimicag.2016.04.026
Abstract

Clostridium difficile Infection (CDI) is the leading cause of infectious healthcare-associated diarrhoea. Recurrent CDI increases disease morbidity and mortality, posing a high burden to patients and a growing economic burden to the healthcare system. Thus, there exists a significant unmet and increasing medical need for new therapies for CDI. This review aims to provide a concise summary of CDI in general and a specific update on ridinilazole (formerly SMT19969), a novel Antibacterial currently under development for the treatment of CDI. Owing to its highly targeted spectrum of activity and ability to spare the normal gut microbiota, ridinilazole provides significant advantages over metronidazole and vancomycin, the mainstay Antibiotics for CDI. Ridinilazole is bactericidal against C. difficile and exhibits a prolonged post-antibiotic effect. Furthermore, treatment with ridinilazole results in decreased toxin production. A phase 1 trial demonstrated that oral ridinilazole is well tolerated and specifically targets clostridia whilst sparing other faecal bacteria. Phase 2 and 3 trials will hopefully further our understanding of the clinical utility of ridinilazole for the treatment of CDI.

Keywords

Antibacterial therapy; Clostridium difficile infection; Gut microbiota; Ridinilazole; SMT19969.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z